UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Tissue distribution of aryl hydrocarbon receptor in the intestine: Implication of putative roles in tumor suppression

Experimental cell research, 2016-05, Vol.343 (2), p.126-134

2016

Volltextzugriff (PDF)

Prognostic utility of tumor-infiltrating lymphocytes in residual tumor after neoadjuvant chemotherapy with trastuzumab for HER2-positive breast cancer

Scientific reports, 2019-02, Vol.9 (1), p.1583-1583, Article 1583

2019

Volltextzugriff (PDF)

Association of L-type amino acid transporter 1 (LAT1) with the immune system and prognosis in invasive breast cancer

Scientific reports, 2022-02, Vol.12 (1), p.2742-2742, Article 2742

2022

Volltextzugriff (PDF)

Clinicopathological values of PD-L1 expression in HER2-positive breast cancer

Scientific reports, 2019-11, Vol.9 (1), p.16662-8, Article 16662

2019

Volltextzugriff (PDF)

Interobserver concordance of Ki67 labeling index in breast cancer: Japan Breast Cancer Research Group Ki67 Ring Study

Cancer science, 2013-11, Vol.104 (11), p.1539-1543

2013

Volltextzugriff (PDF)

Optimal Treatment Duration of Neoadjuvant Endocrine Therapy for Women Aged 60 Years or Older with Estrogen Receptor-Positive, HER2-Negative Invasive Breast Cancer

Journal of Nippon Medical School = Nippon Ika Daigaku zasshi, 2021-08, Vol.88 (4), p.354-360, Article JNMS.2021_88-509

2021

Volltextzugriff (PDF)

Power of PgR expression as a prognostic factor for ER-positive/HER2-negative breast cancer patients at intermediate risk classified by the Ki67 labeling index

BMC cancer, 2017-05, Vol.17 (1), p.354-354, Article 354

2017

Volltextzugriff (PDF)

Impact of combining the progesterone receptor and preoperative endocrine prognostic index (PEPI) as a prognostic factor after neoadjuvant endocrine therapy using aromatase inhibitors in postmenopausal ER positive and HER2 negative breast cancer

PloS one, 2018-08, Vol.13 (8), p.e0201846-e0201846

2018

Volltextzugriff (PDF)

Significance of evaluating tumor-infiltrating lymphocytes (TILs) and programmed cell death-ligand 1 (PD-L1) expression in breast cancer

Medical molecular morphology, 2017-12, Vol.50 (4), p.185-194

2017

Volltextzugriff (PDF)

Cryoablation as the primary treatment in a HER2 positive Stage IV breast cancer patient: 5 years term follow up case report

Current problems in cancer. Case reports, 2024-09, Vol.15, p.100311, Article 100311

2024

Volltextzugriff (PDF)

Induction therapy with paclitaxel and bevacizumab followed by switch maintenance therapy with eribulin in Japanese patients with HER2-negative metastatic breast cancer: a multicenter, collaborative, open-label, phase II clinical study for the SBCCSG 35 investigators

BMC cancer, 2018-06, Vol.18 (1), p.671-671, Article 671

2018

Volltextzugriff (PDF)

Utility of Ki67 labeling index, cyclin D1 expression, and ER-activity level in postmenopausal ER-positive and HER2-negative breast cancer with neoadjuvant chemo-endocrine therapy

PloS one, 2019-05, Vol.14 (5), p.e0217279-e0217279

2019

Volltextzugriff (PDF)

Nuclear grade and comedo necrosis of ductal carcinoma in situ as histopathological eligible criteria for the Japan Clinical Oncology Group 1505 trial: an interobserver agreement study

Japanese journal of clinical oncology, 2021-03, Vol.51 (3), p.434-443

2021

Volltextzugriff (PDF)

Radiotherapy for localized gastric mucosa–associated lymphoid tissue lymphoma: long-term outcomes over 10 years

Journal of radiation research, 2017-07, Vol.58 (4), p.537-542

2017

Volltextzugriff (PDF)

Relationships between pathological factors and long-term outcomes in patients enrolled in two prospective randomized controlled trials comparing the efficacy of oral tegafur–uracil with CMF (N·SAS-BC 01 trial and CUBC trial)

Breast cancer research and treatment, 2021-02, Vol.186 (1), p.135-147

2021

Volltextzugriff (PDF)

Recent trends of HER-2 testing and trastuzumab therapy for breast cancer

Breast cancer (Tokyo, Japan), 2009-10, Vol.16 (4), p.284-287

Kurosumi, Masafumi

2009

Volltextzugriff (PDF)

Comparing protein and mRNA expressions of the human epidermal growth factor receptor family in estrogen receptor-positive breast cancer

Medical molecular morphology, 2019-06, Vol.52 (2), p.90-98

2019

Volltextzugriff (PDF)

Histopathological criteria for assessment of therapeutic response in breast cancer (2007 version)

Breast cancer (Tokyo, Japan), 2008-01, Vol.15 (1), p.5-7

2008

Volltextzugriff (PDF)

Comparison of different definitions of pathologic complete response in operable breast cancer: a pooled analysis of three prospective neoadjuvant studies of JBCRG

Breast cancer (Tokyo, Japan), 2015-11, Vol.22 (6), p.586-595

2015

Volltextzugriff (PDF)

Prognostic significance of subtype and pathologic response in operable breast cancer; a pooled analysis of prospective neoadjuvant studies of JBCRG

Breast cancer (Tokyo, Japan), 2015-09, Vol.22 (5), p.486-495

2015

Volltextzugriff (PDF)

The ubiquitin ligase CHIP acts as an upstream regulator of oncogenic pathways

Nature cell biology, 2009-03, Vol.11 (3), p.312-319

2009

Volltextzugriff (PDF)

Validation of a nuclear grading system for resected stage I–IIIA, high-risk, node-negative invasive breast carcinoma in the N·SAS-BC 01 trial

Breast cancer (Tokyo, Japan), 2022-07, Vol.29 (4), p.720-729

2022

Volltextzugriff (PDF)

Inter-observer agreement among pathologists in grading the pathological response to neoadjuvant chemotherapy in breast cancer

Breast cancer (Tokyo, Japan), 2018-01, Vol.25 (1), p.118-125

2018

Volltextzugriff (PDF)

Histological classification of breast tumors in the General Rules for Clinical and Pathological Recording of Breast Cancer (18th edition)

Breast cancer (Tokyo, Japan), 2020-05, Vol.27 (3), p.309-321

Tsuda, Hitoshi

2020

Volltextzugriff (PDF)

Stat3 up-regulates expression of nicotinamide N-methyltransferase in human cancer cells

Journal of cancer research and clinical oncology, 2008-05, Vol.134 (5), p.551-559

2008

Volltextzugriff (PDF)

1 – 25 von 246

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(207)
Mit Volltextzugriff
(193)

Publikationsform

Artikel
(241)
Berichte
(5)

Sprache

Englisch
(224)
Japanisch
(25)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Tissue distribution of aryl hydrocarbon receptor in the intestine: Implication of putative roles in tumor suppression

Prognostic utility of tumor-infiltrating lymphocytes in residual tumor after neoadjuvant chemotherapy with trastuzumab for HER2-positive breast cancer

Association of L-type amino acid transporter 1 (LAT1) with the immune system and prognosis in invasive breast cancer

Clinicopathological values of PD-L1 expression in HER2-positive breast cancer

Interobserver concordance of Ki67 labeling index in breast cancer: Japan Breast Cancer Research Group Ki67 Ring Study

Optimal Treatment Duration of Neoadjuvant Endocrine Therapy for Women Aged 60 Years or Older with Estrogen Receptor-Positive, HER2-Negative Invasive Breast Cancer

Power of PgR expression as a prognostic factor for ER-positive/HER2-negative breast cancer patients at intermediate risk classified by the Ki67 labeling index

Impact of combining the progesterone receptor and preoperative endocrine prognostic index (PEPI) as a prognostic factor after neoadjuvant endocrine therapy using aromatase inhibitors in postmenopausal ER positive and HER2 negative breast cancer

Significance of evaluating tumor-infiltrating lymphocytes (TILs) and programmed cell death-ligand 1 (PD-L1) expression in breast cancer

Cryoablation as the primary treatment in a HER2 positive Stage IV breast cancer patient: 5 years term follow up case report

Induction therapy with paclitaxel and bevacizumab followed by switch maintenance therapy with eribulin in Japanese patients with HER2-negative metastatic breast cancer: a multicenter, collaborative, open-label, phase II clinical study for the SBCCSG 35 investigators

Utility of Ki67 labeling index, cyclin D1 expression, and ER-activity level in postmenopausal ER-positive and HER2-negative breast cancer with neoadjuvant chemo-endocrine therapy

Nuclear grade and comedo necrosis of ductal carcinoma in situ as histopathological eligible criteria for the Japan Clinical Oncology Group 1505 trial: an interobserver agreement study

Radiotherapy for localized gastric mucosa–associated lymphoid tissue lymphoma: long-term outcomes over 10 years

Relationships between pathological factors and long-term outcomes in patients enrolled in two prospective randomized controlled trials comparing the efficacy of oral tegafur–uracil with CMF (N·SAS-BC 01 trial and CUBC trial)

Recent trends of HER-2 testing and trastuzumab therapy for breast cancer

Comparing protein and mRNA expressions of the human epidermal growth factor receptor family in estrogen receptor-positive breast cancer

Histopathological criteria for assessment of therapeutic response in breast cancer (2007 version)

Comparison of different definitions of pathologic complete response in operable breast cancer: a pooled analysis of three prospective neoadjuvant studies of JBCRG

Prognostic significance of subtype and pathologic response in operable breast cancer; a pooled analysis of prospective neoadjuvant studies of JBCRG

The ubiquitin ligase CHIP acts as an upstream regulator of oncogenic pathways

Validation of a nuclear grading system for resected stage I–IIIA, high-risk, node-negative invasive breast carcinoma in the N·SAS-BC 01 trial

Inter-observer agreement among pathologists in grading the pathological response to neoadjuvant chemotherapy in breast cancer

Histological classification of breast tumors in the General Rules for Clinical and Pathological Recording of Breast Cancer (18th edition)

Stat3 up-regulates expression of nicotinamide N-methyltransferase in human cancer cells

Suchergebnisse filtern